Alterity Therapeutics Advances ATH434 for Multiple System Atrophy: A Rare Neurodegenerative Disease with No Approved Therapies.

Alterity Therapeutics recognizes Multiple System Atrophy (MSA) Awareness Month and the urgent need for disease-modifying treatments. MSA is a rapidly progressive neurodegenerative disease with no approved therapies. Alterity is advancing ATH434, an investigational oral therapy designed to redistribute excess iron in the brain and slow disease progression. The Company has reported meaningful clinical benefit alongside favorable safety and tolerability profiles in its Phase 2 clinical development program evaluating ATH434 in individuals with MSA.